PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Adalimumab - Inflammatory bowel disease

PAD Profile : Adalimumab - Inflammatory bowel disease Important

Keywords :
IBD, biologics, biosimilars, Sequential use of biologic medicines, TNF alpha inhibitor, Cytokine modulator, Crohn's disease, Ulcerative Colitis, UC, immunomodulators
Brand Names Include :
Humira, Amgevita, Imraldi, Hulio, Hyrimoz, Mylan, Yuflyma, Idacio
Important Information :
Adults only. Prescribe by brand.

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
04 October 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway.

05 December 2018
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

ULCERATIVE COLITIS:

The PCN recommends adalimumab dose escalation (40mg weekly OR 80mg fortnightly) in patients with moderately to severely active ulcerative colitis for a 12 week treatment course to recapture response.

Patients must return to standard dosing (40mg fortnightly) after the 12 week course has been completed.

If the patient loses response to the standard dosing within a short time period (1 month) then the provider can apply for funding to return to the escalated dose (40mg weekly OR 80mg fortnightly).

Gastroenterology specialists will be required to repeat the 12 week course if the patient starts to lose response after 1 month of standard dosing (40mg weekly).

Adalimumab is a payment by results excluded drug and will be considered RED on the traffic light system.

Gastroenterology specialists will be required to complete blueteq initiation and continuation forms for the commissioners.

05 December 2018
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

ULCERATIVE COLITIS:

The PCN recommends the sequential use of TNF alpha inhibitors (adalimumab, infliximab or golimumab) in patients with moderately to severely active ulcerative colitis prior to a switch to vedolizumab.

Adalimumab, Infliximab and Golimumab are payment by results excluded drugs and will be considered RED on the traffic light system.

Gastroenterology specialists will be required to complete blueteq initiation and continuation forms for the commissioners.

08 July 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products

Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

Associated BNF Codes

01. Gastro-Intestinal System
01.05.03. Drugs affecting immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More